Clinic Roundup

• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said its SynCon avian influenza vaccine generated protective hemagglutination inhibition titers against six different unmatched strains of H5N1 in a Phase I trial. The vaccine generated an HAI titer of 1:40 or higher against at least one of the six tested strains in eight of 17 (47 percent) immunized subjects; 12 of 17 (71 percent) vaccines generated an HAI titer of 1:20 or higher, indicating a positive vaccine response, against at least one H5N1 strain.